Retrospective Analysis of the Epidemiological Change and Determinants of Prognosis of Talaromycosisof Human Immunodeficiency Virus Negative Host in Guangxi
- Conditions
- To Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of MisdiagnosisTo Study the Recurrence Indicators and Establish a Therapeutic Effect Evaluation System of T. Marneffei Infections
- Interventions
- Other: the multiple programs of antifungal therapy for HIV-negative host
- Registration Number
- NCT03819348
- Lead Sponsor
- Guangxi Medical University
- Brief Summary
Through a multi-center large-sample retrospective study, the epidemiological changes of TSM in Guangxi have been reviewed, its incidence trend was understood to attract the attention of clinicians; the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators. Improve the level of understanding and diagnosis and treatment of HIV-negative TSM in the whole area. A comprehensive efficacy evaluation system and standard treatment program was established to provide a basis for standardized treatment of TSM in HIV-negative hosts. The observational indicators included: 2-week all-cause mortality; 24-week all-cause mortality; clinical improvement time; level of decrease of fungus in the blood culture medium two weeks before treatment; recurrence; appearance of adverse drug reaction at the level 3 and above.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1200
- Eligible patients were HIV-negative adults who had talaromycosis that was confirmed by either microscopy or culture.
- patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description TSM of HIV-negative Host the multiple programs of antifungal therapy for HIV-negative host Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
- Primary Outcome Measures
Name Time Method mortality at 4 week 4 weeks all-cause mortality was defined as the absolute risk of death from any cause during the first 2 weeks after randomization.
clinical remission rate 7 days Clinical resolution of talaromycosis was defined as a temperature of less than 38°C (100°F) for 3 days, resolution of skin lesions, and sterile blood cultures.
recurrence rate 12 months Relapse of talaromycosis was defined as the recurrence of symptoms and a positive fungal culture from any sterile site that led to reinduction of therapy in patients who had achieved clinical resolution.
toxic side effects 24 weeks Side effects were monitored clinically and with the use of hematologic, chemical, and liver-enzyme testing performed at least twice weekly
mortality at week 24 24 weeks The secondary outcome measures were mortality at week 24, the time to clinical resolution of talaromycosis, early fungicidal activity, relapse of talaromycosis, and the incidence of adverse events of grade 3 or higher.
- Secondary Outcome Measures
Name Time Method G test 3 days positive was defined as \>20pg/ml
GM test 3 days positive was defined as \>0.5
Trial Locations
- Locations (1)
Guangxi Medical University
🇨🇳Nanning, Guangxi, China